Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT06341205RecruitingPhase 3
Personalized rituximab for membranous nephropathy using AI
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
BesançonAges 18 years+ - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06352242Recruiting
Study of immune activity after CAR-T therapy for lymphoma
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
MontpellierAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT06325709RecruitingPhase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Bethesda, MarylandAges 18–75 - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT06323213RecruitingPhase 3
Testing a new asthma medicine for severe asthma
This study tests an experimental drug called 610 for people with severe asthma that is not well-controlled with standard medicines. The goal is to see if adding 610 can improve asthma control and reduce flare-ups.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06324604RecruitingPhase 1
Safety study of MTX-101 in healthy adults
This trial tests a new drug called MTX-101 in healthy volunteers to see if it is safe and how the body processes it. It helps determine the right dose before testing in patients with certain conditions.
Heidelberg, VictoriaAges 18–65 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06325280Recruiting
Exercise MRI for Kids with Heart Conditions
This study uses an MRI while exercising to check heart and lung fitness in children with heart disease. It helps doctors learn more about how to care for kids who have had a heart transplant or were born with heart problems.
Edmonton, AlbertaAges 10–18 - NCT06329453Recruiting
Gut immunity and brain health study
This study looks at how your gut's immune system relates to brain and nerve diseases. Researchers will collect samples during a colonoscopy to better understand connections between gut health and neurologic conditions like multiple sclerosis or Parkinson's disease.
North Haven, ConnecticutAges 18–99 - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06331377Recruiting
Study of blood cell disorders for patients 1 year and older
This study looks at people with histiocytic disorders, which are rare conditions where certain immune cells grow too much. It aims to learn more about these disorders to improve diagnosis and treatment.
Rochester, MinnesotaAges 1 year+ - NCT06337097Recruiting
Monitoring heart enzyme during immunotherapy
This study is for people starting immunotherapy with checkpoint inhibitors. It checks a heart enzyme (troponin) to see if the treatment affects your heart, so your doctor can monitor and manage any changes early.
Houston, TexasAges 18 years+ - NCT06333262RecruitingPhase 2
Fixed-duration pirtobrutinib and obinutuzumab for untreated CLL
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Scarborough, MaineAges 18 years+ - NCT06325202Recruiting
A study on preventing low blood sugar with a closed loop system
This trial tests whether a closed-loop insulin pump combined with education can help people with type 1 diabetes better recognize and avoid dangerously low blood sugar. It may be a good fit if you've had diabetes for a long time and have trouble sensing when your blood sugar drops.
La Jolla, CaliforniaAges 18–75 - NCT06329375Recruiting
Food Help for Diabetes Patients After Hospital Stay
This study helps people with diabetes who are admitted to Stanford Hospital and have trouble affording enough food. It provides meals through Mom's Meals after you go home, to make sure you have healthy food options.
Palo Alto, CaliforniaAges 18 years+ - NCT06335888RecruitingPhase 2
Testing a new imaging agent for large vessel vasculitis
This study tests a special radioactive tracer, 18F-AzaFol, to see if it can help diagnose large vessel vasculitis, a type of inflammation in the arteries. The results will be compared with standard FDG PET/CT scans.
BernAges 50 years+ - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT06334341Enrolling by invitation
Study to improve PrEP use in primary care
This trial tests ways to help primary care providers and their patients start using PrEP, a daily pill that prevents HIV. It may be right for you if you are interested in HIV prevention.
Detroit, MichiganAges 18 years+ - NCT06323044Recruiting
Support program for parents giving daily leukemia medicine
This study tests a support program that helps parents give their child's daily leukemia medicine (6-MP) on schedule and overcome any barriers. It aims to make it easier for families to stick with treatment.
Buffalo, New YorkAges Any age - NCT06319430Recruiting
Play study for kids with physical disabilities
This study looks at how children with physical disabilities play using technology. It may help understand their play patterns and needs.
Winnipeg, ManitobaAges 3–9
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.